Answer
The most frequently reported adverse reactions to etranacogene dezaparvovec in clinical studies were headache (31.6%), ALT elevations (22.8%), AST elevations (17.5%) and influenza-like illness (14%), all classified as very common.
Sources for this answer
- HemgenixCSL Behring UK Limited · emc · SmPC §4.8 Undesirable effects · Version 6Document updated
Sources checked